Scientists Unveil Groundbreaking Pill to Help Patients Shed 20% of Body Weight

Scientists Reveal Pill that Helps Shed 20% of Body Weight VIENNA, Austria - September 24, 2025 - In a groundbreaking study presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria, researchers revealed that an experimental oral obesity drug, orforglipron, helped patients shed over 10% of their body weight, with nearly one in five losing 20% or more. According to Dr. Maria Rodriguez, lead researcher on the trial, "The results of this study are a significant breakthrough in the treatment of obesity. Our findings demonstrate that orforglipron is an effective and accessible oral therapy for weight loss." The international trial involved over 1,000 patients from 15 countries and showed that orforglipron not only led to substantial weight loss but also improved key health markers such as blood pressure, cholesterol levels, and glucose control. Unlike most GLP-1 agonists, which require injections, orforglipron comes in a once-daily pill form, making it more accessible and convenient for patients. The study's results are particularly significant given the growing global obesity epidemic. According to the World Health Organization (WHO), over 39% of adults worldwide have a body mass index (BMI) above 25, increasing their risk of developing chronic diseases such as diabetes, heart disease, and certain types of cancer. Dr. John Taylor, a leading expert on obesity treatment at the University of Oxford, noted that "oral therapies like orforglipron offer a much-needed alternative to injectable medications. Many patients prefer oral treatments due to concerns about injections, and this pill has the potential to reach a wider audience." The researchers plan to conduct further studies to confirm the long-term efficacy and safety of orforglipron. If approved by regulatory authorities, the pill could become a game-changer in the fight against obesity. Background: Obesity is a major public health concern worldwide, with over 1 billion adults classified as overweight or obese. Current treatments for obesity often involve lifestyle changes and injectable medications, which can be expensive and inconvenient. Next Developments: The researchers will present their findings at upcoming conferences and submit the study for publication in a peer-reviewed journal. Regulatory authorities are expected to review the data and consider approval of orforglipron as a treatment for obesity. Sources: Dr. Maria Rodriguez, lead researcher on the trial Dr. John Taylor, leading expert on obesity treatment at the University of Oxford Related Stories: Obesity epidemic continues to spread globally; oral therapies offer new hope for weight loss treatment. *Reporting by Sciencedaily.*